Dr. Nathalie Franchimont

New Capabilities

As of September 2026: Overseeing clinical development of afimetoran and the broader pipeline

Beeline Medicines' afimetoran, a once-daily oral pill for lupus, met its primary endpoint in a Phase 2 trial. The result moves the biotech into Phase 3 (pivotal) development for two forms of the disease.

Updated Sep 9